(EN) Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Non Small Cell Lung Cancer: A Registry-based Phase II Randomized Trial
SUPPRESS-NSCLC
NCT04405401
 Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Diane Trudel
514-890-8000 poste 11181
|
(EN) A Phase II Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIA) Non-small Cell Lung Cancer
NeoCOAST-2
NCT05061550
Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Adeline Jouquan
514-890-8000 poste 26214
|
Évaluation de la capacité de déploiement et de la précision d’un système de cathéter détachable hors-scope pour l’ablation des lésions pulmonaires périphériques : Une étude ex vivo sur un modèle de poumon humain
CT0099
NCT04722432
Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Adeline Jouquan
514-890-8000 poste 26214
|
(EN) This is a single-center randomized trial in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibition. Patients will receive standard-of-care immune checkpoint inhibitor (ICI) therapy alone or in combination with a dietary intervention
2023-11332
NCT05805319
Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Wiam Belkaid
514-890-8000
|
Étude multicentrique de phase III, internationale, à double insu et contrôlée par placebo évaluant le traitement néoadjuvant/adjuvant par le durvalumab chez des patients atteints d’un cancer du poumon non à petites cellules de stade II et III résécable
AEGEAN
NCT03800134
Actif en recrutement
|
CISSS DE CHAUDIERE-APPALACHES
 HOTEL-DIEU DE LEVIS
|
|
Pierre Bédard
418-835-7121
|
(EN) A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations
STAR-121
NCT05502237
Actif en recrutement
|
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE
|
|
Christine Giard
450-466-5000 poste 2278
|
(EN) Phase I Trial of Camu Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-Small Cell Lung Cancer and Melanoma
BR-2021-CamuCamu
NCT05303493
Actif en recrutement
|
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE
|
|
Marilyn Tessier
450-466-5000 poste 7691
|
(EN) An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab in Combination With Sacituzumab Govitecan Versus Pembrolizumab Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer
MK-3475-D46 (KEYNOTE D46/EVOKE-03)
NCT05609968
Actif en recrutement
|
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE
|
|
Marilyn Tessier
450-466-5000 poste 7691
|
(EN) A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations
STAR-121
NCT05502237
Actif en recrutement
|
CISSS DES LAURENTIDES
HOPITAL DE SAINT-JEROME
|
|
Yanick Sardin Laframboise
450-431-1020 poste 23429
|
(EN) A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
AVANZAR
NCT05687266
Actif en recrutement
|
CISSS DES LAURENTIDES
HOPITAL DE SAINT-JEROME
|
|
Yanick Sardin Laframboise
450-431-1020 poste 23429
|
Groupe d'étude en oncologie du Québec